MedTrace Logo

Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia

NCT02304770 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2019-06-12

No results posted yet for this study

Summary

The study will examine the effect of aminolaevulinic acid (ALA) photodynamic therapy (PDT) of cervical precancerous lesions in women.

Conditions

  • Cervical Persistent High Risk HPV Infection
  • Cervical Intraepithelial Neoplasia

Interventions

DRUG

Aminolaevulinic acid photodynamic therapy

Aminolaevulinic acid mediated photodynamic therapy

Sponsors & Collaborators

  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Beihua Kong, MD · Qilu Hospital of Shandong University

  • Youzhong Zhang, MD · Qilu Hospital of Shandong University

  • Jining Tao, Master · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304770 on ClinicalTrials.gov